- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT03733483
Sleep Disruption Induced Impairments in Bone Formation (SIIB)
Mechanisms for Sleep/Circadian Disruption-Induced Impairments in Bone Formation
Tutkimuksen yleiskatsaus
Opintotyyppi
Ilmoittautuminen (Todellinen)
Vaihe
- Ei sovellettavissa
Yhteystiedot ja paikat
Opiskelupaikat
-
-
Colorado
-
Aurora, Colorado, Yhdysvallat, 80045
- Clinical & Translational Research Centers (CTRC) UCHealth
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
o Adult men aged 20-65 years old who habitually sleep 7-9 hours/night.
Exclusion Criteria:
- Regularly go to sleep after midnight;
- Shift work 1 year prior to study;
- Travel >1 time zone 4 weeks prior to study or need to travel during study;
- More than moderate activity level (>3 days of exercise per week >30 min of exercise per session);
- Current smokers (or within the previous year of study);
- Positive drug test at screening or laboratory admission;
- BMI > 30 kg/m2;
- Individuals who are concurrently participating in another research protocol that would influence their safe participation in this study. For example, participants involved in a study that requires blood draws or ingestion of experimental medication as this would increase the risk of participation in our study and/or compromise study results.
- Any clinically significant unstable medical or surgical condition within the last year (treated or untreated), including history of a clinically significant abnormality of the neurological system (including cognitive disorders or significant head injury) or any history of seizure (including febrile seizure-sleep loss has been used clinically to induce seizures in patients with epilepsy). Given the wide range of illnesses that are encountered in medical practice, it would not be possible to provide a comprehensive list of each and every disease that could serve as grounds for exclusion for the subject. However, the following is a list of illness categories that would certainly be grounds for exclusion: Connective Tissue and Joint Disorders; Neurologic/cognitive Disorders; Musculoskeletal Disorders; Immune Disorders; Chronobiologic Disorders; Cardiovascular Disorders; Respiratory Disorders; Kidney Disorders; Infectious Diseases; Hematopoietic Disorders; Neoplastic Diseases; and Endocrine and Metabolic Diseases.
Self-reported or newly diagnosed medical condition that is still being investigated or is not under good control, including those identified on screening labs such as:
- Out-of-range values measured on a fasting blood sample: glucose > 100 mg/dl, thyroid stimulating hormone <0.5 or >5.0 uU/ml, abnormal alkaline phosphatase <39 or >117 U/l, creatinine, or hemoglobin <14.5 g/dl men
Any clinically significant psychiatric condition, as defined by DSM-V. Individuals with a history of most psychiatric illnesses or psychiatric disorders will be excluded, such as but not limited to depression, anxiety, alcoholism, drug dependency, schizophrenic disorders, and personality disorders (performed by medical history and physician interview). However, a personal history of limited prior counseling, psychotherapy (e.g., for adjustment reactions) will NOT be exclusionary. Evaluation of Psychiatric/Psychological Suitability:
- Subjects must demonstrate a full understanding of the requirements and demands of the study.
- Each subject will complete psychological screening questionnaires. Exclusionary: Center for Epidemiological Studies Depression (CES-D) ≥ 16;. Subject responses to the CES-D are reviewed immediately and appropriate referrals are made if necessary.
- Individuals who are unaware of specific psychiatric diagnoses who have a history of having been treated with antidepressants, neuroleptic medications or major tranquilizers will be excluded from study.
- Use of anti-depressants or any like therapeutics prescribed by a physician is exclusionary
- Individuals with any clinically significant sleep disorder; Diagnosis or symptoms of sleep disorders (history of significant parasomnia as an adult [night terrors, frequent sleep walking], insomnia, including but not limited to hypersomnias such as apnea, periodic limb movements, narcolepsy). Sleep disorders will be screened by self-report and physician interview including use of validated sleep questionnaires (PSQI, Epworth sleepiness scale, and Berlin sleep questionnaire for sleep apnea).
- Individuals on medications known to affect bone turnover (e.g. glucocorticoids, osteoporosis medications);
- Use of medications/supplements/drugs that impact sleep or bone metabolism (such as but not limited to sleep medications, marijuana etc.) within one month (participants can be studied at a later date).
- Dwelling below Denver altitude (1,600 m) 6 months prior to testing;
- Greater than moderate caffeine (>500 mg/day) or alcohol use (>14 standard drinks/week or >5 drinks in one sitting);
- Subjects with a history of heparin-induced thrombocytopenia (HIT) or an allergy to heparin;
- Inability to travel to the CU-AMC campus for study visits.
- Individuals with restrictive diets (e.g., vegan)
- Individuals with 25OHD < 20 ng/mL;
- Individuals with eGFR < 60 mL/min/1.73m2 as this is known to affect CTX measurements;
- T-score ≤ -2.5 (men ≥50 years old) or Z-score < -2.0 (men <50 years old) for bone mineral density (BMD) at the L-spine, femoral neck, or total hip on baseline DXA as compared to the DXA machine's normative database;
- Symptoms of active illness (e.g., fever); note that subject can be studied at a later date.
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Muut
- Jako: Ei käytössä
- Inventiomalli: Yksittäinen ryhmätehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
---|---|
Kokeellinen: Sleep Deprivation
|
Participants in this arm will sleep for 8 hours at their habitual time for 1 week outpatient.
Food will be provided for the outpatient week by the study.
After the outpatient week participants will check into our inpatient Clinical Translational Research Center (CTRC) for a 9 day inpatient stay.
During their inpatient stay participants will be sleep restricted to a 5 hour/night sleep opportunity for nights 2-7 of their inpatient stay.
Outcome measures include a 24-hour serum draw (urine and blood) which will occur on night 1 (pre) and night 8 (post).
Patients will be given a 10 + hour recovery sleep period on night 8 of their inpatient stay.
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
Change in Serum Pro-collagen 1 Intact N-terminal Propeptide (P1NP)
Aikaikkuna: 24 hour serum draw before and after 6 night sleep restriction. Pre measures taken on night 1 through day 2. Post measures taken on night 7 through day 8. A fasting blood sample will be taken each morning of the inpatient stay.
|
A marker of bone formation
|
24 hour serum draw before and after 6 night sleep restriction. Pre measures taken on night 1 through day 2. Post measures taken on night 7 through day 8. A fasting blood sample will be taken each morning of the inpatient stay.
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
Change in Serum C-telopeptide of Type 1 Collagen (CTX)
Aikaikkuna: 24 hour serum draw before and after 6 night sleep restriction. Pre measures taken on night 1 through day 2. Post measures taken on night 7 through day 8. A fasting blood sample will be taken each morning of the inpatient stay.
|
A marker of bone resorption
|
24 hour serum draw before and after 6 night sleep restriction. Pre measures taken on night 1 through day 2. Post measures taken on night 7 through day 8. A fasting blood sample will be taken each morning of the inpatient stay.
|
Yhteistyökumppanit ja tutkijat
Sponsori
Tutkijat
- Päätutkija: Christine Swanson, MD, MCR, University of Colorado, Denver
Julkaisuja ja hyödyllisiä linkkejä
Yleiset julkaisut
- Swanson CM, Shea SA, Wolfe P, Cain SW, Munch M, Vujovic N, Czeisler CA, Buxton OM, Orwoll ES. Bone Turnover Markers After Sleep Restriction and Circadian Disruption: A Mechanism for Sleep-Related Bone Loss in Humans. J Clin Endocrinol Metab. 2017 Oct 1;102(10):3722-3730. doi: 10.1210/jc.2017-01147.
- Swanson CM, Shanbhag P, Tussey EJ, Rynders CA, Wright KP Jr, Kohrt WM. Bone Turnover Markers After Six Nights of Insufficient Sleep and Subsequent Recovery Sleep in Healthy Men. Calcif Tissue Int. 2022 Jun;110(6):712-722. doi: 10.1007/s00223-022-00950-8. Epub 2022 Feb 8.
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Todellinen)
Opintojen valmistuminen (Todellinen)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muut tutkimustunnusnumerot
- 18-0015
- K23AR070275 (Yhdysvaltain NIH-apuraha/sopimus)
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .
Kliiniset tutkimukset Sleep Deprivation
-
University of Michigan Rogel Cancer CenterBreast Cancer Research FoundationValmisRintasyöpä | Unettomuus | Eturauhassyöpä | Paksusuolen syöpäYhdysvallat
-
Kaiser PermanenteAktiivinen, ei rekrytointiUnettomuus | Obstruktiivinen uniapnea (OSA) | Levottomat jalat -oireyhtymä (RLS) | Hypersomnia tyyppi; Nukkumishäiriö | Vuorotyön unihäiriötYhdysvallat
-
VA Office of Research and DevelopmentValmis
-
Neurovalens Ltd.Clinical Trial MentorsPeruutettuPTSD | Unettomuus | Unihäiriöt
-
University of South FloridaRekrytointiOppositiivinen uhmahäiriö | Krooninen unettomuusYhdysvallat
-
Taipei Medical University Shuang Ho HospitalCase Western Reserve UniversityRekrytointiAivohalvaus, akuutti | Unihäiriöinen hengitys | Uni-arkkitehtuuriTaiwan
-
IWK Health CentreValmisNukkumishäiriöKanada
-
Massachusetts General HospitalEi vielä rekrytointiaUnettomuus | Syövän selviytymistä
-
Cereve, Inc.Valmis